Literature DB >> 1875332

HIV protease: a novel chemotherapeutic target for AIDS.

J R Huff1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1875332     DOI: 10.1021/jm00112a001

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  52 in total

1.  In search of gamma-secretase: presenilin at the cutting edge.

Authors:  D J Selkoe; M S Wolfe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes.

Authors:  A Kiriyama; T Nishiura; H Yamaji; K Takada
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

3.  LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads.

Authors:  H J Böhm
Journal:  J Comput Aided Mol Des       Date:  1992-12       Impact factor: 3.686

4.  Molecular dynamics studies on HIV-1 protease: a comparison of the flap motions between wild type protease and the M46I/G51D double mutant.

Authors:  Antonino Lauria; Mario Ippolito; Anna Maria Almerico
Journal:  J Mol Model       Date:  2007-09-06       Impact factor: 1.810

5.  Solvent accessibility as a predictive tool for the free energy of inhibitor binding to the HIV-1 protease.

Authors:  V Nauchitel; M C Villaverde; F Sussman
Journal:  Protein Sci       Date:  1995-07       Impact factor: 6.725

Review 6.  Resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors:  D Boden; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers.

Authors:  M Sudoh; G M Pauletti; W Yao; W Moser; A Yokoyama; A Pasternak; P A Sprengeler; A B Smith; R Hirschmann; R T Borchardt
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

Review 8.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Authors:  D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Preparation and preliminary characterization of poly(ethylene glycol)-pepstatin conjugate.

Authors:  J Brygier; J Vincentelli; M Nijs; C Guermant; C Paul; D Baeyens-Volant; Y Looze
Journal:  Appl Biochem Biotechnol       Date:  1994-04       Impact factor: 2.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.